Skip to main content
Canna~Fangled Abstracts

O-1602, an Agonist of Atypical Cannabinoid Receptors GPR55, Reverses the Symptoms of Depression and Detrusor Overactivity in Rats Subjected to Corticosterone Treatment

By July 9, 2020August 1st, 2020No Comments

. 2020 Jul 8;11:1002.

doi: 10.3389/fphar.2020.01002. eCollection 2020.

Andrzej Wróbel 1, Anna Serefko 2, Aleksandra Szopa 2, Daniela Ulrich 3, Ewa Poleszak 2, Tomasz Rechberger 1
Affiliations

Abstract

In view of the fact that GPR55 receptors are localized in brain areas implicated in the pathophysiology of depression, GPR55 gene expression is reduced in the dorsolateral prefrontal cortex of suicide victims, and GPR55 receptor agonism exerts an anxiolytic-like effect, GPR55 receptors have drawn our attention as a potential target in the treatment of mood disorders. Therefore, in the present study, we wanted to check whether a 7-day intravenous administration of O-1602 (0.25 mg/kg/day) – a phytocannabinoid-like analogue of cannabidiol that belongs to the agonists of GPR55 receptors, was able to reverse the corticosterone-induced depressive-like behavior accompanied by detrusor overactivity in female Wistar rats. Additionally, we tried to determine the influence of GPR55 stimulation on the bladder, hippocampal and urine levels of several biomarkers that play a role in the functioning of the urinary bladder and/or the pathophysiology of depression. Our experiments showed that O-1602 therapy improved signs of depression (measured by the forced swim test) and detrusor contractility (measured by conscious cystometry) in animals exposed to the corticosterone treatment. Moreover, the treatment reduced the oxidative damage in the urinary bladder and neuroinflammation (observed as the reduction of elevated levels of 3-NIT, MAL, and IL-1β, TNF-α, CRF, respectively). The O-1602 treatment also reversed the abnormal changes in the bladder, hippocampal or urine values of CGRP, OCT3, VAChT, BDNF, and NGF. The above-mentioned findings allow to suggest that in the future the modulation of atypical cannabinoid receptors GPR55 could have a potential role in the treatment of depression and overactive bladder.

 

Keywords: O-1602, depression, detrusor overactivity, rats, receptor GPR55

Figures

Figure 1

Figure 2

Figure 3

Figure 4

References

    1. Abrams P., Andersson K. E. (2007). Muscarinic receptor antagonists for overactive bladder. BJU Int. 100, 987–1006. 10.1111/j.1464-410X.2007.07205.x – DOI – PubMed
    1. Alavi M. S., Hosseinzadeh H., Shamsizadeh A., Roohbakhsh A. (2016). The effect of O-1602, an atypical cannabinoid, on morphine-induced conditioned place preference and physical dependence. Pharmacol. Rep. 68, 592–597. 10.1016/j.pharep.2015.12.009 – DOI – PubMed
    1. Alavi M. S., Shamsizadeh A., Azhdari-Zarmehri H., Roohbakhsh A. (2018). Orphan G protein-coupled receptors: The role in CNS disorders. BioMed. Pharmacother. 98, 222–232. 10.1016/j.biopha.2017.12.056 – DOI – PubMed
    1. Bakali E., McDonald J., Elliott R. A., Lambert D. G., Tincello D. G. (2016). Cannabinoid receptor expression in the bladder is altered in detrusor overactivity. Int. Urogynecol. J. 27, 129–139. 10.1007/s00192-015-2802-x – DOI – PubMed
    1. Baker D., Pryce G., Davies W. L., Hiley C. R. (2006). In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol. Sci. 27, 1–4. 10.1016/j.tips.2005.11.003 – DOI –PubMed

Leave a Reply